Mechanism of action of metformin in nonalcoholic steatohepatitis: Authors' reply

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 5, 2009, Pages 603-604

  Loomba, R ^a   Kleiner, D E ^b   Hoofnagle, J H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

DRUG MECHANISM; FERRITIN BLOOD LEVEL; INSULIN RESISTANCE; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; LETTER; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 59149106109     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03916.x     Document Type: Letter

References (6)

1. Mascitelli L, Pezzetta F, Goldstein MR. Mechanism of action of metformin in nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009 29 : 602 3.
2. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005 310 : 1642 6.
3. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998 21 : 62 8.
4. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001 96 : 2448 55.
5. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: Pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009 29 : 172 82.
6. Rowe JW, Wands JR, Mezey E, et al. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred. Medicine (Baltimore) 1977 56 : 197 211.